Akebia Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $236.2M | $160.2M | $194.6M | $292.6M | $213.6M | $295.3M | $335.0M | $207.7M |
| Auryxia product revenue net | $181.5M | $152.2M | $170.3M | $177.1M | $142.2M | $128.9M | $111.1M | $6.8M |
| Vafseo product revenue net | $45.8M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Collaboration revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| License collaboration and other revenue | $8.9M | $8.0M | $24.3M | $115.5M | $71.4M | $166.4M | $223.9M | $200.9M |
| Cost of Revenue | $39.5M | $63.2M | $74.1M | $85.6M | $150.7M | $296.5M | $145.3M | $7.8M |
| Gross Profit | $196.7M | $97.0M | $120.5M | $207.0M | $62.9M | $-1.2M | $189.7M | $200.0M |
| Gross Margin | 83.3% | 60.6% | 61.9% | 70.8% | 29.5% | -0.4% | 56.6% | 96.3% |
| Operating Expenses | ||||||||
| Research & Development | $62.4M | $37.7M | $63.1M | $130.0M | $147.9M | $218.5M | $323.0M | $291.0M |
| SG&A Expense | $107.5M | $106.5M | $100.2M | $138.6M | $174.1M | $154.1M | $149.5M | $87.1M |
| Operating Income | $23.5M | $-50.5M | $-46.3M | $-80.8M | $-264.5M | $-377.8M | $-286.3M | $-178.2M |
| Operating Margin | 9.9% | -31.5% | -23.8% | -27.6% | -123.8% | -127.9% | -85.5% | -85.8% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-3.7M | $-69.4M | $-51.9M | $-94.2M | $-282.0M | $-384.8M | $-286.3M | $-171.9M |
| Income Tax Expense | $1.6M | $0 | $0 | $0 | $0 | $0 | $-6.6M | $-28.3M |
| Net Income | $-5.3M | $-69.4M | $-51.9M | $-94.2M | $-282.0M | $-384.8M | $-279.7M | $-143.6M |
| Net Margin | -2.3% | -43.3% | -26.7% | -32.2% | -132.0% | -130.3% | -83.5% | -69.1% |
| EPS (Basic) | $-0.02 | $-0.33 | $-0.28 | $-0.52 | $-1.70 | $-2.78 | $-2.36 | $-2.47 |
| EPS (Diluted) | $-0.02 | $-0.33 | $-0.28 | $-0.52 | $-1.70 | $-2.78 | $-2.36 | $-2.47 |
| Shares Outstanding (Basic) | 257.2M | 210.9M | 187.5M | 182.8M | 165.9M | 138.5M | 118.4M | 116.9M |
| Shares Outstanding (Diluted) | 257.2M | 210.9M | 187.5M | 182.8M | 165.9M | 138.5M | 118.4M | 116.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |